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Abstract

Background and Purpose: T-type calcium (Cav3) and transient receptor potential vanilloid-1 (TRPV1)
channels play central roles in the control of excitability in the peripheral nervous system and are regarded as
potential therapeutic pain targets. Modulators that either activate or inhibit TRPV1-mediated currents display
analgesic properties in various pain models despite opposing effects on their connate target, TRPV1. We
explored the effects of TRPV1-active compounds on Cav3-mediated currents.
Experimental Approach: Whole-cell patch clamp recordings were used to examine the effects of TRPV1-active
compounds on rat dorsal root ganglion low voltage-activated calcium currents and recombinant Cav3
isoforms in expression systems.
Key Results: The classical TRPV1 agonist capsaicin as well as TRPV1 antagonists A-889425, BCTC, and
capsazepine directly inhibited Cav3 channels. These compounds altered the voltage-dependence of activation
and inactivation of Cav3 channels and delayed their recovery from inactivation, leading to a concomitant
decrease in T-type current availability. The TRPV1 antagonist capsazepine potently inhibited Cav3.1 and 3.2
channels (KD < 120 nM), as demonstrated by its slow off rate. In contrast, neither the TRPV1 agonists,
Palvanil and resiniferatoxin, nor the TRPV1 antagonist AMG9810 modulated Cav3-mediated currents.
Conclusions and Implications: Analgesic TRPV1-active compounds inhibit Cav3 currents in native and
heterologous systems. Hence, their analgesic effects may not be exclusively attributed to their actions on
TRPV1, which has important implications in the current understanding of nociceptive pathways. Importantly,
our results highlight the need for attention in the experimental design used to address the analgesic properties
of Cav3 channel inhibitors.
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BACKGROUND AND PURPOSE
T-type calcium (Cav3) and transient receptor potential vanilloid-1 (TRPV1) channels
play central roles in the control of excitability in the peripheral nervous system and are regarded
as potential therapeutic pain targets. Modulators that either activate or inhibit TRPV1-mediated
currents display analgesic properties in various pain models despite opposing effects on their
connate target, TRPV1. We explore the effects of TRPV1-active compounds on Cav3-mediated
currents.
EXPERIMENTAL APPROACH
Whole-cell patch clamp recordings were used to examine the effects of TRPV1-active
compounds on rat dorsal root ganglion low voltage-activated calcium currents and recombinant
Cav3 isoforms in expression systems.
KEY RESULTS
The classical TRPV1 agonist capsaicin as well as TRPV1 antagonists A-889425,
BCTC, and capsazepine directly inhibited Cav3 channels. These compounds alter the voltage
dependence of activation and inactivation of Cav3 channels and delay their recovery from
inactivation, leading to a concomitant decrease in T-type current availability. The TRPV1
antagonist capsazepine potently inhibits Cav3.1 and 3.2 channels (KD<120 nM) evidenced by
its slow off-rate. In contrast, neither the TRPV1 agonists, Palvanil and resiniferatoxin, nor the
TRPV1 antagonist AMG9810 modulated Cav3-mediated currents.
CONCLUSIONS AND IMPLICATIONS
Analgesic TRPV1-active compounds inhibit Cav3 currents in native and heterologous
systems. Hence, their analgesic effects may not be exclusively attributed to their actions on
TRPV1, which has important implications in the current understanding of nociceptive
pathways. Importantly, our results highlight the need for attention in the experimental design
used to address the analgesic properties of Cav3 channel inhibitors.
KEYWORDS
T-type calcium channels; TRPV1; Capsaicin; Capsazepine, BCTC; A-889425
ABBREVIATIONS
Dorsal root ganglion (DRG); transient receptor potential (TRP) channels; voltage-gated
calcium channel (Cav); high voltage-activated (HVA); low-voltage-activated (LVA); steadystate inactivation (SSI); half-maximal excitatory concentration (EC50); half-maximal inhibitory
concentration (IC50); Hill coefficient (nH); N-(4-tert-butylphenyl)-4-(3-chloropyridin-2yl)piperazine-1-carboxamide
(BCTC);
1-(3-methylpyridin-2-yl)-N-(4(trifluoromethylsulfonyl)phenyl)-1,2,3,6-tetrahydropyridine-4-carboxamide (A-889425).
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INTRODUCTION
T-type calcium channels, or Cav3s, are voltage-gated calcium selective channels that,
compared to other Cavs, activate at less depolarized potentials (Catterall et al., 2003). This
property makes Cav3 channels particularly important in the regulation of cell excitability (Cain
et al., 2010). Numerous studies have documented the critical roles played by T-type calcium
channels in the control of neuronal firing modalities and demonstrate their involvement in
neuronal low-threshold burst firing (Cain et al., 2010). It has been shown that upregulation of
Cav3 expression is a common feature of various conditions that involve hyperexcitability such
as chronic pain. For example, Cav3 channels are upregulated in dorsal root ganglion (DRG)
neurons of various animal models of pain (Jagodic et al., 2008; Kang et al., 2018; Wen et al.,
2010; Yue et al., 2013), visceral hypersensitivity (Marger et al., 2011) and experimental models
of diabetes (Cao et al., 2011; Jagodic et al., 2007; Obradovic et al., 2014). Moreover, their
abundance in peripheral nociceptors has attracted much attention to Cav3 channels as analgesic
targets for the treatment of pain with numerous novel drugs being developed targeting Cav3s
that show promising potent analgesic effects (For recent review see (Snutch et al., 2018)).
Within the Cav3 family, Cav3.2 is the predominant isoform expressed in sensory
neurons implicated in nociceptive signalling (Bourinet et al., 2005). Additionally, Cav3.2
knockin/flox studies marked their relevance in setting up the firing threshold of low-threshold
mechanoreceptors (LTMRs) Aδ- and C-LTMRs (Francois et al., 2015); whereas genetic
ablation of Cav3.2 in C-LTMRs validates their role in the noxious mechanical cold, light-touch
and chemical perception that underlie various forms of neuropathic pain. Although Cav3.1
channels have been relatively lesser explored, this isoform was recently implicated in the
pathophysiology of trigeminal neuropathic pain (Choi et al., 2016).
T-type calcium channels (Cav3s) and transient receptor potential vanilloid 1 (TRPV1)
receptor co-localize in various neuronal types in the periphery (Cardenas et al., 1995) and both
have been implicated in pain signal generation. Capsaicin, the pungently painful compound
found in hot chili peppers from the capsicum family, is the classical agonist of the TRPV1
receptor whose activation mediates Ca2+ influx and excitation in several neuronal types. This
property guided the identification of TRPV1 channels (Caterina et al., 1997) and subsequently
the development of synthetic TRPV1 antagonist, capsazepine (Bevan et al., 1992). TRPV1 is
a polymodal receptor abundantly expressed in sensory neurons where it responds to a variety
of noxious stimuli including, heat, low pH, and chemical irritants (Caterina et al., 1997; Jordt
et al., 2000). As a non-selective cation channel, TRPV1 activation leads to local membrane
depolarization which initiates a cascade of events that trigger opening of voltage-gated sodium
channels responsible of the upstroke of the action potential, and propagation of the noxious
signal. Therefore, inhibition of TRPV1-mediated currents is considered one of the mechanisms
behind some forms of analgesia. Indeed, the classical TRPV1 agonist, capsaicin, and
antagonist, capsazepine, both exhibit analgesic properties in various pain assays, despite of
their opposing effects on this vanilloid receptor (See recent review (Moran et al., 2018)).
Capsazepine’s analgesic action is conceptualized as a consequence of decreasing TRPV1mediated currents that support hyperexcitability. Conversely, capsaicin promotes TRPV1
opening, which is initially perceived as heat or pain, and at a later phase analgesia. This
apparent paradoxical effect has been explained by a capsaicin-induced desensitization of
TRPV1 that causes quiescence in hyperactive pain neurons.
Capsaicin is used as a topical analgesic in “low-concentration” creams (0.1% or ~3
mM) that have poor efficacy in the treatment of neuropathic pain (Derry et al., 2012); or
improved efficacy “high concentration” patches (8% or ~260 mM) (Noto et al., 2009). These
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doses are several fold higher (>50,000, lower limit) than those required to activate the human
isoform of TRPV1 (EC50 ~0.05-0.3 µM) (Li et al., 2011). At such high concentrations, offtarget effects become significant and a clear mechanism for its analgesic effects is difficult to
ascertain. Both capsaicin and capsazepine also modulate other membrane receptors and ion
channels, particularly the voltage-dependent Cavs (Castillo et al., 2007; Docherty et al., 1997;
Hagenacker et al., 2005). However, many reports have been based on native low voltageactivated (LVA) calcium currents without expression system verification and therefore a direct
effect of these compounds over Cav3-mediated currents is missing. It has been suggested that
low-concentration capsaicin modulation of LVA and HVA calcium currents in DRG neurons
occurs via a TRPV1-mediated mechanism (Comunanza et al., 2011; Kerckhove et al., 2014;
Wu et al., 2005). This has recently been shown to occur via an intracellular calcium-dependent
mechanism (Cazade et al., 2017; Comunanza et al., 2011), leading to inhibition of Cav3mediated currents, caused by the influx of Ca2+ through activated TRPV1. To-date, the
mechanism of direct capsaicin inhibition of Cav3s has not been addressed.
TRPV1 and Cav3 channels co-localize in various neuronal types in the periphery
(Cardenas et al., 1995) and both channel families have been implicated in pain signalling. In
the present study, we investigated Cav3s as a potential off-target of TRPV1 modulators. Wholecell patch clamp recording was used to assess native T-type calcium currents in DRG neurons
and heterologously expressed Cav3s to determine their mode of action. Our results show that
several but not all TRPV1 modulators are capable of direct inhibition of Cav3s in the absence
of TRPV1.

1. METHODS
1.1. Cell culture and transfection
HEK293 cells containing the SV40 Large T-antigen (HEK293T, CRL-3216, ATCC,
USA, RRID:CVCL_0063) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM,
Invitrogen Life Technologies, Australia), supplemented with 10% fetal bovine serum (FBS,
Bovigen, Australia), 1% penicillin and streptomycin (Pen/Strep, Invitrogen Life
Technologies), and 1x GlutaMAX supplement (Invitrogen Life Technologies) at 37°C, 5%
CO2. In all experiments HEK293T cells were transiently co-transfected using calcium
phosphate with plasmid cDNAs encoding human Cav3.1 (provided by Dr G. Zamponi), human
Cav3.2 (a1Ha-pcDNA3 was a gift from Dr E. Perez-Reyes, Addgene #45809 (Cribbs et al.,
1998)), human Cav3.3 (a1Ic-HE3-pcDNA3 also from Dr E. Perez-Reyes, Addgene #45810
(Gomora et al., 2002)) or rat TRPV1 in combination with green fluorescent protein. Cells were
transfected in solution and plated on 12mm glass coverslips for patching within 24-72 hrs.
After 8-12 hrs, transfection medium was replaced with fresh culture media and cells were
incubated at 30°C, 5% CO2 to allow adequate expression.
1.2. Dorsal root ganglion isolation and culture
DRGs were isolated from neonatal (P0-P2) Sprague Dawley rats (ArcCrl:CD(SD)IGS,
Animal Resources Centre, Australia, RRID:RGD_8553001) following decapitation, as
approved by the University of Wollongong Animal Ethics Committee (AE17/23), in
compliance with BJP policy on reporting experiments involving animals and with the
principles of ARRIVE and the United States NIH. Rats were housed in double decker,
individually ventilated cages containing corncob bedding, nesting material, chewing block,
PVC tunnel and a plastic or cardboard shelter. Rats were housed at 21oC on a 12 hour light/dark
4

cycle, and fed Vella Rat Pellets and water ad libitum. Briefly, DRG ganglia were collected, by
hemisecting the spinal cord and removing individual DRG ganglia, in ice cold divalent free
Hanks Buffered Saline Solution (HBSS) where dorsal root and peripheral nerve processes were
carefully trimmed. DRG ganglia were transferred to dissociation media (divalent free HBSS
with 2mg/ml Collagenase Type II, Worthington, USA) for 60 min at 37°C, 5% CO2. Digested
DRG ganglia were spun for 10 min at 200g at 23°C and the supernatant discarded. The DRG
neurons were washed with fresh DMEM (supplemented with 10% FBS, 1x GlutaMAX and 1%
Penicillin/Streptomycin) followed by trituration with progressively smaller diameter fire
polished Pasteur pipettes. Dissociated DRG neurons were then filtered through a 160µm nylon
mesh (Millipore, Australia) to remove cell debris and non-dissociated material. The DRG
neuron suspension was then plated on poly-L-lysine and laminin coated 12mm cover glass
(Sigma, Australia), and left to attach for ~3 hours at 37°C, 5% CO2 after which ~1mL of fresh
DMEM (10% FBS, 1x GlutaMAX and 1% Pen/Strep) was added and incubated overnight.
Primary DRG cultures were held at 30°C and recorded within 48 hrs.
1.3. Electrophysiology of native low voltage-activated (LVA) calcium currents
Whole-cell patch clamp recording of DRG neurons were carried out 1-2 days post
isolation. DRG neurons were perfused with extracellular solution containing (mM): 140 TEACl, 10 CaCl2, 1 MgCl2, 10 D-Glucose, 10 HEPES, pH 7.4 with TEA-OH (~320 mOsmol·kg-1).
Borosilicate patch pipettes (World Precision Instruments, USA) were fire-polished to a
resistance of 1-3 MΩ and filled with intracellular solution containing (mM): 150 CsCl, 1.5
MgCl2, 5 EGTA, 10 HEPES, pH 7.2 with CsOH (~300 mOsmol·kg-1). Depolarizationactivated calcium currents (ICa) were recorded at room temperature (22-24°C) using a
MultiClamp 700B amplifier (Molecular Devices, USA), digitalized via a Digidata 1440
controlled by pClamp10.7 acquisition system. LVA ICa were elicited from a holding potential
(Vh) of −90 mV with a step depolarization of 100 ms to −40 mV at 0.2 Hz. Compounds were
superfused to the neuron using a syringe pump (New Era Pump Systems Inc, USA) loaded with
1ml syringe connected to a 50 cm MicroFil 28G (World Precision Instruments, USA) at 2
µl/min allowing fast solution exchanges.
1.4. Electrophysiology of transiently transfected Cav3s
Whole-cell patch recordings of HEK293T cells were carried out 1-3 days post
transfection at room temperature. Cells were constantly perfused with extracellular solution
containing (mM): 100 NaCl, 10 CaCl2, 1 MgCl2, 5 CsCl, 30 TEA-Cl, 10 Glucose, 10 HEPES,
pH7.4 with TEA-OH (~320 mOsmol·kg-1). Fire-polished borosilicate pipettes (1-3mΩ) were
filled with intracellular solution containing (mM): 140 K-Gluconate, 5 NaCl, 2 MgCl2, 5
EGTA, 10 HEPES, pH 7.4 with KOH (~300 mOsmol·kg-1).
Calcium currents were elicited by 100 ms depolarizing test pulses to −20 mV or a 180
ms ramp from −90 mV to +70 mV from a holding potential of −90 mV at 0.2 Hz. Activation
curves were generated from stimulation protocols consisting of a series of depolarizing test
pulses from −90 to +20 mV (Δ10 mV, Vh −90 mV) at 0.2 Hz before and after compound
application. Similarly, steady-state inactivation (SSI) was assessed by the peak current
amplitude at −20 mV (50 ms) achieved after 1s pre-pulses (from −90 mV to +10 mV, Δ5 mV).
Recovery from inactivation was recorded using a standard double pulse protocol (Vh −90 mV)
consisting of a 100 ms (hCav3.1 or hCav3.2) or 150 ms (hCav3.3) pulse to −20 mV (P1) that
achieved complete inactivation, followed by a second 20 ms test pulse (P2) to −20 mV after
progressively increasing inter-pulse intervals (from 0 to 10s).

5

1.5. Data and statistical analysis
Data analysis and graphs were generated using OriginPro (Origin Lab Corporation,
USA, RRID:SCR_014212). Concentration-response curves for each compound were
constructed from ≥5 individual experiments per concentration tested. Fractional current,
determined as the ratio between peak current in the presence of compound (IComp) over peak
current determined prior to application (ICTR, was plotted against the compounds concentration.
Curves were fit with a Hill equation of following:
𝐼𝐼𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶

� 𝐼𝐼

𝐶𝐶𝐶𝐶𝐶𝐶

�=1+

[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶]ℎ

𝐼𝐼𝐼𝐼50 ℎ +[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶]ℎ

where h is the Hill coefficient (nH), IC50 is the half-maximal inhibitory concentration. Activation
and SSI curves were generated from 5-16 independent experiments and fit with a modified
Boltzmann equation of the form:
𝐺𝐺 = 1/(1 + exp((𝑉𝑉𝑡𝑡 − 𝑉𝑉0.5 )/𝑘𝑘𝑘𝑘

where Vt is the test potential, V0.5 is the half-maximal activation potential and ka is the slope
factor related to the voltage dependence. Recovery from inactivation plots were fit using a
single (Cav3.3) or double (Cav3.1 and Cav3.2) exponential of the following equations,
𝑃𝑃2

𝑃𝑃2

𝑡𝑡

(𝑃𝑃1) = 1 + 𝐴𝐴𝑓𝑓𝑎𝑎𝑠𝑠𝑠𝑠 ∗ exp �− τ�

( 𝑃𝑃1) = 1 + 𝐴𝐴𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 ∗ exp �− 𝜏𝜏

𝑡𝑡

𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓

� + 𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 ∗ exp �− 𝜏𝜏

𝑡𝑡

𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

�

where τ is the fast and slow time constant and A is the amplitude of the fast and slow
components.
Compound block and unblock kinetics (kon and koff) were measured by fitting the peak currents
for successive depolarizations during toxin wash-in or wash-out with a single exponential to
determine, τon and τoff, of the following equation,
𝑡𝑡
𝑦𝑦(𝑡𝑡) = 𝐴𝐴 ∗ exp �− � + 𝐵𝐵

τ

From the observed τon and τoff, we calculated kon and koff with the following equations.

τ𝑜𝑜𝑜𝑜 =

1
𝑘𝑘𝑜𝑜𝑜𝑜 ∗ [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶] + 𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜

τ𝑜𝑜𝑜𝑜𝑜𝑜 = 1/𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜

where [Comp] is the concentration of compound applied. These rate constants were used to
calculate the equilibrium dissociation constant, KD by the following equation,
𝐾𝐾𝐷𝐷 = 𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜 /𝑘𝑘𝑜𝑜𝑜𝑜

The data and statistical analysis comply with the recommendations on experimental design and
analysis in pharmacology (Curtis et al., 2015). As our experiments were conducted on isolated
DRG neurons from a combined pool of DRGs from several rats, animals were not randomized,
and each cell served as its own control. The nature of the experiments, which are for the most
part perfusing known concentrations of a compound onto single cells, make blinding
impractical. Statistical significance (P < 0.05) was determined using unpaired Student’s t-test.
All data is presented as mean ± SEM (n).
6

1.6. Materials
All test compounds were dissolved in DMSO to generate stock solutions of 10 or 100
mM, according to the manufacturer’s instructions. Capsaicin (Sigma-Aldrich, Australia),
Resiniferatoxin and Capsazepine (Abcam, Australia), A-889425, BCTC, AMG9810, and Npalmitoyl-vanillamide (Palvanil, Alomone, Israel) were diluted in extracellular solution to the
required final concentrations. The maximal DMSO concentration during recordings was 0.5%
and did not cause any detectable changes in Cav3 Ca2+ currents (ICa) under our experimental
conditions (data not shown).
1.7. Nomenclature of Targets and Ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries
in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017).
2. RESULTS
2.1. Capsaicin and Capsazepine inhibit rat DRG neuron LVA calcium currents
At room temperature, the shallow voltage dependence and low open probability of
TRPV1 channels allows the evaluation of the effects of capsaicinoid compounds, such as
capsaicin and capsazepine, on native LVA ICa at physiological membrane potentials. High
extracellular TEA concentrations were used to inhibit both endogenous K+- and TRPV1mediated currents (Rivera-Acevedo et al., 2012). We recorded LVA ICa from neonatal
(medium diameter, 30-40 µm) DRG neurons with a test pulse to −40 mV from a holding
potential (Vh) of −90 mV (Figure 1A). Control LVA ICa (black trace) were recorded before 100
µM application of capsaicin (red, Figure 1A, i), or capsazepine (purple, Figure 1A, ii). Currents
after a 5 min washout (shown in grey) qualitatively demonstrate differences in reversibility of
both compounds. At 100 µM, capsaicin inhibited 93 ± 0.9% (n=5) of the total LVA ICa elicited
by the test pulse (Figure 1B), and its effect was completely reversed upon washout (Figure 1A
i). In contrast, capsazepine (100 µM) reduced the LVA ICa almost completely (98.3 ± 1.8%;
n=5; Figure 1B) whilst its effects were poorly reversed (<10%) during 5 min washout (Figure
1A ii). These results show that capsaicin and capsazepine inhibit native T-type calcium currents
in neonatal rat DRG neurons with distinct unblocking kinetics.
2.2. TRPV1-active compounds that inhibit recombinant Cav3 channels
A panel of TRPV1 agonists and antagonists commonly used in the study of TRPVs
(Figure 2A) were screened against the human isoforms of the T-type calcium channels at a
concentration of 10 µM (Figure 2B). hCav3.1, hCav3.2 and hCav3.2 were expressed in
HEK293T cells and whole-cell patch clamp recordings were used to monitor effects on ICa in
the presence of TRPV1 agonists: capsaicin, resiniferatoxin, and Palvanil, and TRPV1
antagonists: capsazepine, BCTC, AMG9810, and A-889425 (Figure 2B). Neither Palvanil
(n=5) nor resiniferatoxin (n=5) elicited any obvious effects on human Cav3-mediated current
at 10 µM. Nevertheless, at the same concentration, capsaicin was able to modestly inhibit all
three family members (Cav3.1: 22.5 ± 2.3%, n=6; Cav3.2: 28.5 ± 3.5%, n=5; Cav3.3: 32.6 ±
0.9%, n=5). From the panel of TRPV1 antagonists, capsazepine, A-889425, and BCTC at 10
µM robustly inhibited (>50%) human Cav3.1, 3.2 and 3.3 channels (Figure 2B). At the same
concentration, however, AMG9810 (n=5) was ineffective at modulating the recombinant Cav3
currents.
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Concentration-response curves for the inhibition of Cav3-mediated currents were
generated for capsaicin, A-889425 and BCTC (Figure 2C, each concentration on the
concentration-response relationship contains ≥5 individual points). Cav3.1 channels were most
potently inhibited by A-889425 (IC50: 3.2 ± 0.4 µM; nH: 0.9±0.1), followed by BCTC (IC50:
10.2 ± 0.3 µM; nH: 1.5±0.1) and capsaicin (IC50: 26.4 ± 1.4 µM; nH: 1.4±0.1) (Figure 2C, left).
In the case of Cav3.2, BCTC and A-889425 displayed comparable potencies (IC50: 3.4 ± 0.3
µM, nH: 1.0±0.1; and IC50: 4.8 ± 0.3 µM, nH: 1.4±0.1; respectively), whereas the IC50 obtained
for capsaicin was 23.6 ± 1.4 µM (nH: 1.1±0.1, Figure 2C, middle). Similarly, A-889425 and
BCTC were equipotent at Cav3.3 (5.8 ± 0.4 µM; nH: 1.5±0.1; and 6.9 ± 0.4 µM; nH: 1.1±0.1,
respectively), whereas capsaicin inhibited 50% of Cav3.3 currents at 16.3 ± 0.5 µM (nH:
1.2±0.04; Figure 2C, right). Thus, capsaicin, A-889425 and BCTC are capable of inhibiting all
three hCav3s, whereas Palvanil, AMG9810 or resiniferatoxin do not inhibit.
Due to significantly slower blocking kinetics, application of low concentrations of
capsazepine (<10 µM) would imply washins extending > 30 min (Supplementary Figure 1).
Therefore the potency of this compound was estimated from its blocking kinetics to Cav3
channels (described in section 2.3) rather than concentration-response relationships.
2.3. Activation of TRPV1 by capsaicin indirectly inhibits Cav3 channels and depends
strictly on Ca2+ influx.
Previous studies have described T-type Ca2+ current inhibition by low doses of TRPV1agonists in DRG neurons (Comunanza et al., 2011; Kerckhove et al., 2014). In the present
study, this observation was verified and expanded in detail through co-expression experiments
of TRPV1 and Cav3.1 in HEK293 cells.
In the absence of calcium, Cav3 channels can conduct Na+ efficiently (Khan et al., 2008;
Senatore et al., 2014), thus robust inward and outward T-type currents can be elicited and
measurement of channel block under calcium free conditions can be quantified (Figure 3).
When co-expressed with TRPV1 channels, Cav3.1 currents are easily distinguished by
their voltage dependence and kinetics (Figure 3) and thus we can evaluate the effects of
activating TRPV1 with capsaicin at a concentration (1 µM) that does not directly block Cav3.1
(Figure 2C, left panel). Ramp stimuli (−90 to +70 mV; 180 ms, 0.2 Hz; Figure 3A) were applied
to cells expressing Cav3.1 alone (3A/D) and to cells where Cav3.1 and TRPV1 (3B/E) were cotransfected. Recordings in Na+ based solutions with 10 mM Ca2+ (Figure 3A/B) or zero external
Ca2+ (Figure 3D/E) are shown. In the presence of 10 mM extracellular Ca2+, peak inward
currents at −15 mV are elicited (Figure 3A/B, black traces). Application of capsaicin to cells
expressing Cav3.1 did not alter the elicited current (Figure 3A) nor channel activation or steadystate inactivation properties. Conversely, capsaicin applied to cells co-expressing Cav3.1 and
TRPV1 caused a robust outwardly rectifying TRPV1 current that quickly desensitized (Figure
3B). The influx of Ca2+ through TRPV1 produced a leftward shift in the peak Cav3.1 current
(Figure 3B, red trace) which was irreversible after a 5 min washout (Figure 3B, grey trace).
This shift in the ramp current was mirrored by hyperpolarizing shifts in both channel activation
and steady-state inactivation from square pulse protocols (Figure 3C and Table 1).
A different response occurs in the absence of Ca2+ which allows Na+ to become the
main charge carrier. Under these conditions, the currents elicited by the ramp protocol peak at
−30mV (Figure 3D/E, black traces). When Cav3.1 is expressed alone, Na+ currents elicited
during the ramp protocol were unchanged (Figure 3D), similar to that seen when Ca2+ was the
charge carrier. However, when TRPV1 is co-expressed with Cav3.1, TRPV1 activation by 1
µM capsaicin caused the similar non-desensitizing outwardly rectifying current as those
observed in 10 mM Ca2+ (Figure 3E, red trace). The modest enhancement of inward peak
current is likely due to the compounded TRPV1 and Cav3.1 currents, that remain unaltered
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after washout (Figure 3E, grey trace), as reflected by the plots shown in Figure 3F. The coexpression experiments show that indirect inhibition of T-type currents by low capsaicin
concentrations in cells where TRPV1 and Cav3s channels are present occurs via Ca2+ influx
through activated TRPV1 channels.
2.4. Capsaicin and capsazepine display distinctive unblock kinetics
In contrast to the effects of capsaicin, inhibition of LVA ICa in DRGs by capsazepine
was not reversible within the experimental constrains of patch clamp recordings and thus we
studied their blocking kinetics using the heterologous system. Representative current traces
elicited by a 100 ms depolarizing stimulus to −20 mV (Vh: −90 mV, 0.2 Hz) are shown in
Figure 4A/B (red: 100 µM capsaicin; purple: 100 µM capsazepine; black: control; grey:
washout). The time course of Cav3 current inhibition (washin) and its recovery (washout) upon
exposure to capsaicin and capsazepine were examined (Figure 5). Representative diary plots
are displayed and coloured accordingly (arrows correspond to current traces depicted in Figure
4). In agreement with the DRG data, >98% inhibition of Cav3 current was observed in the
presence of 100 µM capsazepine whereas application of 100 µM capsaicin spares ~5-15% of
the elicited ICa across the three hCav3’s (Figure 4A/B and Figure 5).
In the experiments shown, a clear difference in unblocking kinetics can be observed
between capsaicin and capsazepine where the off rate, koff, for capsazepine is significantly less
than for capsaicin, but with comparable on rates (kon) (Table 2 and Figure 5). Accordingly, kon’s
of capsaicin and capsazepine for both Cav3.1 and Cav3.2 are similar (~0.004 s-1µM-1) and
contrast with their interaction with Cav3.3 (Table 2). Capsaicin blocks Cav3.3 ~1.5x faster (kon
= 0.0057 ± 0.0003 s-1µM-1), whereas capsazepine exhibits a ~2x slower blocking rate towards
this channel (kon = 0.0019 ± 0.0002 s-1µM-1). Interestingly, capsazepine’s off-rates are radically
slower than those of capsaicin as can be readily observed in the diary plots. Figure 5 shows that
capsazepine washouts (ICa recovery) extended for several hundreds of seconds often reaching
only partial recovery of the control current (<10%). Hence, the estimated koff for capsazepine
at Cav3.2 and Cav3.1 channels were ~400-fold and 180-fold slower than those of capsaicin to
the same channels, respectively (see Table 2). From these blocking rates, the apparent
dissociation constants (KD) for capsaicin were calculated for each channel isoform (19.6, 18.8
and 7.45 µM for hCav3.1, hCav3.2 and hCav3.3, respectively, Table 2) which are consistent
with the IC50’s determined from concentration-response relationships (Figure 2C). As expected
from the observed slow koffs, capsazepine dissociation constants from Cav3.1 and Cav3.2
channels are in the low nanomolar range (120 and 46 nM, respectively) suggesting a much
tighter interaction between this TRPV1 inhibitor and the nociceptive channels Cav3.2 and
Cav3.1, than to their connate receptor. Interestingly, the observed blocking kinetics and,
consequently, the KD for capsazepine at Cav3.3 was 2.0 µM (Table 2) which may serve as a
molecular tool to dissect the contribution of this isoform in native LVA ICa.
Taken together, these results support a strong inhibitory action of several TRPV1-active
compounds on T-type calcium channel activity at a concentration range well below those
commonly use to cause analgesia.
2.5. TRPV1-active compounds decrease Cav3 availability
Voltage-dependent activation and steady-state inactivation
In order to understand the mechanism of inhibition of T-type calcium channels by
capsaicin, BCTC, and A889425 we investigated their actions on the biophysical properties of
Cav3-mediated currents. Figure 6 summarizes the effects of 30 µM capsaicin on T-type currents
exhibiting a consistent depolarizing shift in activation for all three channels (Cav3.1: +5.5 mV;
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Cav3.2: +2.0 mV; and Cav3.3: +13.1 mV). Furthermore, hyperpolarizing shifts in steady-state
inactivation were also observed for all Cav3 isoforms (Cav3.1: −8.2 mV; Cav3.2: −2.0 mV; and
Cav3.3: −11.6 mV) (Figure 6A and Table 3). Interestingly, the slowest of the T-types, Cav3.3
displayed larger apparent shifts in activation and steady-state inactivation than the other two
family members.
Compared to capsaicin, BCTC and A-889425 are more potent inhibitors of all three
Cav3s (Figure 2), therefore their effects on T-type channel voltage-dependent properties were
investigated at a concentration of 10 µM (Figure 6). All three small molecules, capsaicin,
BTCT and A-889425, affected the voltage-dependent properties of Cav3.1 and 3.3 channels
comparably. However, BCTC and A-889425 shifted their steady-state inactivation further in
the hyperpolarizing direction (>8 mV, Table 3). In contrast, the voltage dependence of Cav3.2
kinetics was the least affected by TRPV1-active compounds, highlighting this isoform’s unique
biophysical properties.
Recovery from inactivation
A double-pulse protocol was used to evaluate the influence of capsaicin, BCTC and A889425 on the recovery from inactivation of T-type channels. A control pulse of sufficient
duration (P1, −20 mV, 100 ms or 150 ms) was used to drive all channels into the inactivated
state which was then followed by progressively longer inter-pulses at the holding potential,
then a second test pulse P2 (see figure 6B inset) was applied before and after application of the
TRPV1-active molecules. In control conditions, the recovery from inactivation of Cav3.1 and
Cav3.2 is better approximated by the sum of two exponential functions whereas Cav3.3 can be
satisfactorily fit with a single exponential (Figure 6B). All three compounds significantly
delayed the recovery of Cav3s from inactivation. The quantification of such effect revealed that
in the presence of capsaicin, both recovery time constants (fast and slow) increased ~2-fold,
with a significant increase in the relative amplitude of the slow component (from 0.30 ± 0.07
control to 0.44 ± 0.05 in the presence of capsaicin) (Figure 6B and Table 3). The major effect
of capsaicin on Cav3.2 recovery from inactivation was a significant increase in the proportion
of the slow component of the recovery (0.28 ± 0.04 versus 0.74 ± 0.03). Accordingly, we
observed a decrease in recovery from inactivation in Cav3.3 currents determined by the slowing
of the time constant (τ = 0.38 ± 0.01 s for control versus τ = 0.52 ± 0.01 s in the presence of
capsaicin, Table 3). Examination of Cav3 channel recovery from inactivation in the presence
of BCTC and A-889425 showed larger effects than those seen for capsaicin (Figure 6B and
Table 3) but with overall similar trends. For Cav3.1, both BCTC and A-889425 increased both
time constants and the proportion of τslow component (Table 3). For Cav3.2, the fast and slow
time constants were not significantly altered but a large increase in the proportion of τslow
component was observed (CTR: 0.28±0.04, vs BCTC: 0.74±0.03, and A-889425: 0.96±0.05).
BCTC slowed the recovery from inactivation ~2-fold for hCav3.3 whereas A-889425
demonstrated a larger ~4-fold slowing in recovery from inactivation (Figure 6B).
Across the Cav3s, the mechanisms of inhibition by capsaicin, BCTC and A-889425
were consistent with a decrease in channel activity. The changes in voltage-dependent gating,
activation rightward shift and inactivation leftward shift, together with the significant delay in
recovery from inactivation of these TRPV1-active compounds act synergistically to decrease
the available T-type current at membrane potentials where these channels are known to regulate
excitability.
3. DISCUSSION
In this study, we report the direct modulation of native and recombinant T-type calcium
channels by TRPV1-active compounds that are considered analgesic. We evaluated molecules
known to activate TRPV1 (capsaicin, Palvanil and resiniferatoxin) as well as those that
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antagonise it (capsazepine, BCTC, A-889425 and AMG9810). Our results demonstrate that
capsaicin, capsazepine, BCTC and A-889425 are effective Cav3 channel inhibitors at
concentrations well below those used clinically to produce analgesia (Brandt et al., 2012).
Interestingly, Palvanil, AMG9810 and resiniferatoxin did not modulate Cav3s despite being
structurally and chemically related to the other TRPV1-active compounds tested (Figure 2A).
In the TRPV1 cryo-EM structures, overlapping density for both capsaicin and resiniferatoxin,
describes a common vanilloid binding pocket within the voltage-sensing domain, enclosed by
the S3 and S4 transmembrane segments (Cao et al., 2013). Given that resiniferatoxin does not
inhibit Cav3s, this suggests a divergent binding site from that described as the vanilloid binding
pocket in TRPV1.
3.1. Capsaicin and capsazepine modulate DRG LVA calcium currents.
We have shown that 100 µM capsaicin or capsazepine inhibits >95% of the LVA ICa in
rat DRGs neurons of 30-40 µm diameter which typically belong to the Aδ (thinly myelinated)
high- and low- threshold mechanoreceptors (Fang et al., 2005) (Figure 1A). However, in
contrast to capsaicin’s effect, capsazepine inhibition of LVA ICa in primary sensory neurons
essentially (Fig.1A i,ii). Previous studies have proposed that capsazepine inhibits voltage-gated
calcium channels (VGCC) directly (Docherty et al., 1997), and furthermore it has been
proposed that, in rat DRG neurons, capsaicin inhibits VGCCs in a TRPV1-dependent manner
(Hagenacker et al., 2005; Wu et al., 2005). An earlier study showed ~10% inhibition of LVA
ICa in rat DRG by 0.1 µM capsaicin, however higher concentrations of this drug were not tested
(Hagenacker et al., 2005). Similarly, capsazepine effects have been examined over HVA
calcium currents in rat DRG neurons (IC50 = 1.4-7.7µM, (Wu et al., 2005)) with similarly slow
off kinetics as reported in this study. In order to unequivocally ascertain the direct effects of
these two compounds on T-type channels, we show their inhibitory actions on heterologously
expressed Cav3s in mammalian cells.
3.2. TRPV1-active compounds inhibit Cav3 channels directly
Agonists and antagonists of TRPV1 channels negatively modulated recombinant
Cav3.1-3 channel currents. Capsaicin, capsazepine, BCTC and A-889425 were shown to
directly inhibit Cav3-mediated currents (Figure 2). Furthermore, differential effects of other
TRPV1-active molecules like Palvanil, resiniferatoxin or AMG9810, that were unable to
modulate Cav3 function, can rule out major endogenous TRPV1-mediated effect in our
heterologous system. Previous studies have described irreversible T-type Ca2+ current
inhibition by low concentrations of TRPV1-agonists in DRG neurons (Comunanza et al., 2011;
Kerckhove et al., 2014). In this study, we show that this inhibition depends strictly on Ca2+,
likely via Ca2+ entry through capsaicin-activated TRPV1 triggering intracellular feedback
mechanisms as proposed elsewhere (Cazade et al., 2017; Comunanza et al., 2011; Kerckhove
et al., 2014). Therefore, in tissues where TRPV1 and Cav3 channels coexist, low concentrations
of TRPV1-activators (AM404 and capsaicin) irreversibly decrease T-type current by a TRPV1mediated intracellular Ca2+ increase. At high concentrations, capsaicin inhibits Cav3 currents
directly and reversibly, as reflected by the apparent lower affinity estimated in the present
study. Thus, the mechanisms of inhibition of Cav3 channels by capsaicin can be distinct but
both lead to the loss of T-type current, which in turn supports their contribution in the analgesic
effects of TRPV1 channels activators.
The kinetics of block by capsaicin, A-889425 and BCTC were amenable to IC50
determination (Figure 2C), whereas capsazepine’s kinetics were too slow for reliable
determination of an IC50, hence we estimated its dissociation constant KD from on- and offrates of block (Table 2). A-889425 was the most potent inhibitor across the Cav3 family,
followed by BCTC and capsaicin. There were, however, differences in the selectivity patterns
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across Cav3s. Both capsaicin and BCTC exerted their stronger effects on Cav3.1 channels
whereas A-889425 had the highest potency for Cav3.3.
Analyses of Cav3 biophysical properties in the presence of capsaicin, A-889425 and
BCTC’s shed light on the inhibitory mechanism of action of these small molecules.
Consistently, all three compounds decreased the availability of the three T-type channel
isoforms by a strong delay in their recovery from inactivation, a leftward shift of inactivation
and shifting activation to more positive potentials.
Endogenous cannabinoids, including anandamide, have been shown to directly inhibit
T-type calcium channels and to activate TRPV1 (Chemin et al., 2001). Anandamide has a long
unsaturated fatty acyl chain and thus is chemically similar to many vanilloids. A detailed study
of the molecular determinants of anandamide inhibition, showed that potency increased with
the level of unsaturation in the alkyl chain of various derivatives (Chemin et al., 2007).
Consistent with this report, we observed that unsaturated capsaicin (Fig. 2A) blocks Cav3
channels, whereas fully saturated Palvanil (Fig. 2A) did not exhibit any obvious modulatory
effects on T-type currents. Other TRPV1-active compounds including N-arachidonoyl
dopamine, N-arachidonoyl 5-HT and AM404 have also been shown to inhibit Cav3 channels
directly (Gilmore et al., 2012; Kerckhove et al., 2014; Ross et al., 2009). The novel orthophenoxylanilide derivative, MONIRO-1, also slows recovery from inactivation kinetics of
Cav3 channels (McArthur et al., 2018) suggesting a common mechanism of action between
structurally related small molecules on Cav3 channels.
3.3. TRPV1 actions and Cav3 inhibition
Direct comparison of IC50s between TRPV1 and Cav3s, as measures of their potency,
of the aforementioned compounds reveals a clear preference of these substances for TRPV1
channels. For example, A-889425 and BCTC display 10-100-fold higher affinity for TRPV1
channels than for Cav3s (Chaudhari et al., 2013; McGaraughty et al., 2008). With the caveat
that our KD estimate for capsazepine’s inhibition of T-type channels does not necessarily
represent an equilibrium reaction, the values obtained for Cav3.1 and 3.2 are 3- to 6-fold lower
than the reported concentration for half-maximal inhibition of TRPV1-mediated currents
(Caterina et al., 1997).
Capsaicin activates TRPV1 channels at concentrations 30- to 1,000-fold (McIntyre et
al., 2001; Voets et al., 2004) lower than those inhibiting Cav3 channels directly. Strikingly,
when used as an analgesic, topically applied capsaicin doses range between ~3-260 mM (0.18%) (Derry et al., 2012; Noto et al., 2009). At such high concentrations, it can be assumed that
all the available T-type calcium currents may be inhibited by the drug, either due to indirect
inhibition by Ca2+ influx through TRPV1 or directly. Considering that Cav3s, and in particular
Cav3.2 channels, have been implicated as key regulators of neuronal excitability in the
periphery, and as bona fide pharmacological targets in the treatment of pain. It is tempting to
infer that at least some of the analgesic effects attributed to capsaicin are mediated via the
reduction of Cav3.2 channel currents in sensory neurons.
To our knowledge, this is the first systematic study of the modulation of analgesic
TRPV1-active compounds over T-type calcium channels in native and recombinant systems.
We demonstrate that several of these small molecules inhibit Cav3 channels by a common
mechanism based on decreasing the availability of the T-type calcium channels at
physiologically relevant potentials. Furthermore, our results propose an alternative explanation
as to why TRPV1 antagonist and its agonist capsaicin can be analgesic in various pain assays.
At clinically relevant doses, inhibition of Cav3s in sensory neurons may constitute a component
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of analgesia. Thus, these findings offer an alternative explanation to the apparent disparate
analgesic effects of the TRPV1 agonist capsaicin.
3.4. A cautionary note on capsaicin induced pain in animal models
Capsaicin and other small molecules have been used experimentally to induce and
estimate hyperalgesia as well as allodynia. Following intradermal and topical application,
capsaicin initiates nociceptive C-fibre activity and within seconds to minutes, the skin
sensitivity is enhanced causing pain upon which desensitization may ensue. Thus, capsaicin is
considered an important tool in the study of pain and it is used to probe the analgesic potential
of various compounds, despite capsaicin-induced pain model’s propensity to significant
variability, in estimating allodynia and hyperalgesia. Here, we show that capsaicin both directly
and indirectly inhibits Cav3s emphasizing that perhaps it is not surprising that selective Cav3
channel drugs, such as ABT-639, are not analgesic in the intradermal capsaicin pain model in
which the routinely used capsaicin doses likely abolish all T-type current (Wallace et al., 2016).
This may explain the apparent failure of potential T-type channel active drugs in alleviating
capsaicin-induced pain and raises a cautionary note towards the inadequacy of this assay to
evaluate the analgesic effects of T-type calcium channel drugs.

4. CONCLUSION
In this study, we demonstrate cross-reactivity between TRPV1-active analgesic
compounds (agonists and antagonists) and Cav3 isoforms in rat DRG neurons and
heterologously expressed human Cav3 isoforms. The findings raise the possibility that some of
the analgesic effects elicited by the aforementioned compounds may arise through inhibition
of Cav3s in the periphery and may explain why both TRPV1 agonists and antagonists can be
analgesic in various pain assays. We provide a possible mechanism to explain why some Ttype channel drugs fail to alleviate capsaicin-induced pain models and why this analgesic assay
may not be a suitable for the study of T-type calcium channel inhibiting drugs. Although
capsaicin and BCTC are >100-fold more selective for TRPV1 over Cav3s, A-889425 is only
10-100-fold less potent, whereas capsazepine is more selective for hCav3.1 and hCav3.2 over
TRPV1 largely due to an extremely slow off-rate. At clinical concentrations of capsaicin
(topical application in the mM range), T-type calcium channels may also be inhibited. These
results highlight the potential of using TRPV1 channel drugs as templates from which to design
more selective and potent inhibitors of Cav3s as novel analgesic therapeutic compounds.
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BULLET POINT SUMMARY
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• Description of the modulation of rat and human T-type calcium channels by TRPV1active compounds
Clinical significance:
• Some analgesic effects of TRPV1-active compounds may arise from inhibition of Ttype calcium channels
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Figure Legends
Figure 1. TRPV1 agonist (Capsaicin) and antagonist (Capsazepine) inhibit LVA calcium
currents in rat DRG neurons. (A) Representative LVA calcium currents elicited by a 100 ms
depolarizing pulse to −40 mV (Vh= −90 mV, 0.2 Hz, see voltage protocol bottom inset) in
control (black), capsaicin (red, i) or capsazepine (purple, ii) and after a 5 minute washout
(grey). (B) Bar graph depicting % inhibition of LVA calcium currents in DRG neurons by 100
µM capsaicin (red, n=5) and 100 µM capsazepine (purple, n=5).
Figure 2. TRPV1 agonists and antagonists inhibit heterologously expressed hCav3 isoforms in
a concentration-dependent manor. (A) Chemical structures of TRPV1-active compounds
comprising agonists and antagonists used in this study. (B) Bar graph showing percent
inhibition of hCav3.1 (crosshatch), hCav3.2 (solid) and hCav3.3 (diagonal) by 10 µM capsaicin
(n≥5), capsazepine (n=5), Palvanil (n=5), BCTC (n≥11), AMG 9810 (n=5), A-889425 (n≥13)
and resiniferatoxin (n=5). (C) Concentration-response relationships obtained for capsaicin
(red), A-889425 (orange) and BCTC (blue) on hCav3.1 (left), hCav3.2 (middle) or hCav3.3
(right) calcium currents.
Figure 3. Modulatory effects of Cav3.1 currents by permeant ions and co-expression of
TRPV1. Representative ramp traces of hCav3.1 with Ca2+ (A) or Na+ (D) as the permeant ion
or hCav3.1 co-expressed with TRPV1 with Ca2+ (B) or Na+ (E) as the permeant ion. Current
traces obtained in the absence (control, black), in the presence of 1 µM capsaicin (red) or after
washout (grey). In part (A) and (D), control, capsaicin and washout traces are overlayed.
Activation (triangle) and steady-state inactivation (square) curves when Ca2+ (C) or Na+ (F) is
the permeant ion. When hCav3.1 is expressed alone (filled) or co-expressed with TRPV1 (open)
in absence (black) or presence of 1 µM capsaicin (red).
Figure 4. Representative calcium currents of Cav3 isoforms in the presence of TRPV1-active
compounds. Representative currents mediated by hCav3.1 (top), hCav3.2 (middle) and hCav3.3
(bottom) in control (black) conditions, after application of (A) 100 µM capsaicin (red), (B) 100
µM capsazepine (purple), (C) 10 µM BCTC (blue) or (D) 10 µM A-889425 and washout (grey)
elicited from Vh = −90 mV by a test pulse to −20 mV (100 ms, 0.2 Hz) and normalized to peak
control current values (Scale bars are X: 0.2 nA; Y: 50 ms). (E) Percentage recovery after 5
minutes of washout.
Figure 5. Comparison of capsazepine and capsaicin blocking and unblocking kinetics on Cav3
channels. Time course of representative whole-cell calcium current inhibition for (A) capsaicin
or (B) capsazepine. Bar showing time course of capsaicin (red) or capsazepine (purple)
application. Coloured arrows depict time points of traces shown in Figure 4 (A/B).
Figure 6. Effects of TRPV1-active compounds on voltage-dependent activation, steady-state
inactivation, and recovery from inactivation. (A) Activation (triangle) and steady-state
inactivation (square) curves in control (black), 30 µM capsaicin (red), 10 µM BCTC (blue) or
10 µM A-889425 for hCav3.1 (top, n=16 control activation, n=9 control SSI, n=6 capsaicin
activation, n=6 capsaicin SSI, n=5 BCTC activation, n=5 BCTC SSI, n=6 A-889425 activation,
n=5 A-889425 SSI), hCav3.2 (middle, n=11 control activation, n=10 control SSI, n=8 capsaicin
activation, n=5 capsaicin SSI, n=5 BCTC activation, n=5 BCTC SSI, n=5 A-889425 activation,
n=5 A-889425 SSI) and hCav3.3 (bottom, n=11 control activation, n=5 control SSI, n=7
capsaicin activation, n=6 capsaicin, n=6 BCTC activation, n=5 BCTC SSI, n=6 A-889425
activation, n=5 A-889425 SSI). (B) Recovery from inactivation in the absence (control, black),
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and presence of 30 µM capsaicin (red), 10 µM BCTC (blue) or 10 µM A-889425 for hCav3.1
(top, n=5), hCav3.2 (middle, n=7 control; n=5 capsaicin, BCTC and A-889425) and hCav3.3
(bottom, n=5).
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Table 1. Comparison of activation and steady-state inactivation parameters for hCav3.1 and
hCav3.1 + TRPV1 channels obtained with extracellular Ca2+ or Na+ in the absence and presence
of capsaicin (1 µM)
Parameters

Ca2+

V0.5 Act (mV)
V0.5 Inact (mV)

-27.0.± 0.2
-47.2 ± 0.1

Cav3.1
Ca2+
capsaicin
-20.9 ± 0.3
-53.4 ±0.5

Na+

Na+
capsaicin

Ca2+

-2.6 ± 0.8
-72.0 ± 0.3

-4.0 ± 1.2
-72.3 ± 0.2

-24.6 ± 0.5
-54.2 ±0.5

Cav3.1 + TRPV1
Ca2+
Na+
capsaicin

Na+
capsaicin

-40.8 ± 0.5
-67.0 ± 0.1

-2.8 ± 1.1
-72.4 ±0.4

-6.2 ± 0.8
-72.4 ± 0.2
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Table 2. Capsaicin and capsazepine kinetic rate constants for inhibition of Cav3.1, 3.2 and 3.3.
Parameters
kon (s-1µM-1)
koff (s-1)
KD (µM)

Capsaicin

hCav3.1
Capsazepine

0.0039±0.0004
n=6
0.077±0.003
n=6
19.6

0.0036±0.0004
n=9
0.00043±0.00004*
n=7
0.12

Capsaicin

hCav3.2
Capsazepine

0.0037±0.0003
n=6
0.069±0.007
n=6
18.8

0.0036±0.0005
n=5
0.00017±0.00002*
n=5
0.046

hCav3.3
Capsaicin
Capsazepine
0.0057±0.0003
n=6
0.043±0.003
n=8
7.45

(* significantly different between Capsaicin and Capsazepine kinetics)

0.0019±0.0002*
n=6
0.0037±0.0008*
n=5
2.0
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Table 3. Comparison of activation, steady-state inactivation, recovery from inactivation, and macroscopic current activation and inactivation time
constants parameters for hCav3.1, 3.2 and 3.3 channels obtained in the absence (control) and presence of capsaicin (30 µM), BCTC (10 µM) and
A-889425 (10 µM).
Parameters
V0.5 Act
(mV)
V0.5 Inact
(mV)
τfast (Afast)
(s)
τslow(Aslow)
(s)
τact
(ms)
τinact
(ms)

Control

hCav3.1
Capsaicin
BCTC

A-889425

Control

hCav3.2
Capsaicin
BCTC

A-889425

control

hCav3.3
Capsaicin
BCTC

A-889425

-26.96±0.19

-21.48±0.40*

-30.38±0.34*

-27.53±0.48

-28.38±0.57

-26.39±0.36*

-22.48±0.60*

-25.27±0.23*

-24.88±0.36

-11.76±0.50*

-18.86±0.49*

-19.36±0.55*

-47.16±0.14

-55.39±0.14*

-59.07±0.25*

-66.37±0.33*

-51.46±0.42

-53.49±0.37*

-51.13±0.42

-52.54±0.32

-44.64±0.49

-56.22±0.36*

-56.56±0.29*

-57.03±0.38*

0.07±0.01
(0.70±0.07)
0.32±0.06
(0.30±0.07)

0.16±0.01*
(0.56±0.05)
0.56±0.04*
(0.44±0.05)

0.23±0.01*
(0.62±0.03)
1.17±0.08*
(0.37±0.03)

0.21±0.03*
(0.46±0.05)
1.06±0.09*
(0.54±0.06)

0.38±0.03
(0.65±0.04)
2.18±0.32
(0.28±0.04)

0.34±0.04
(0.23±0.03)
1.61±0.06
(0.74±0.03)

0.39±0.03
(0.22±0.07)
2.21±0.21
(0.77±0.07)

0.26±0.61
(0.03±0.05)
2.54±0.17
(0.96±0.05)

0.38±0.01

0.52±0.01*

0.72±0.02*

1.47±0.04*

N/A

N/A

N/A

N/A

2.45±0.26

2.25±0.33

2.01±0.19

2.44±0.29

4.41±0.28

3.54±0.15

5.18±0.45

4.37±0.42

14.35±1.30

9.88±1.41

11.65±1.65

13.64±1.28

11.40±0.60

10.20±1.16

10.71±0.92

10.16±1.25

14.62±0.77

13.60±0.72

15.88±1.18

16.82±0.57

22.02±1.68

17.03±1.19

17.63±1.32

23.69±1.39

(* significantly different from Control)
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